Cara Therapeutics (CARA) EV/EBITDA US GAAP (year values) |
||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | |||
| EV/EBITDA | ? | -250.3 | 1.71 | 0.49 | -12.8 | -322.2 | -1 495 | |
| Changes by years, y/y, % | -105% | -101% | -71% | -2 710% | +2 422% | |||
Cara Therapeutics. EV/EBITDA
Cara Therapeutics. EV/EBITDA, changes, %
Cara Therapeutics (CARA) EV/EBITDA US GAAP (quarter values) |
||||||||
| FY2025Q1 | FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2026Q1 | LTM ? | |||
| EV/EBITDA | ? | -5.82 | 3.49 | 5.37 | -257.2 | -208.5 | -1 495 | |
| Changes by years, y/y, % | -2 975% | +661% | -184% | +1 562% | +3 479% | |||
| Changes by quarters, q/q, % | -62% | -160% | +54% | -4 889% | -19% | |||